Skip to main content
رجوع
Watch Compare

DiaMedica Therapeutics Inc.

جودة البيانات: 83%
DMAC
Nasdaq Manufacturing Chemicals
KWD 6.22
▲ KWD 0.03 (0.48%)
القيمة السوقية: 335.15 M
السعر
KWD 6.22
القيمة السوقية
335.15 M
نطاق اليوم
KWD 5.85 — KWD 6.32
نطاق 52 أسبوعًا
KWD 3.28 — KWD 10.42
حجم التداول
186,198
فتح KWD 6.20
متوسط 50 يوم / 200 يوم
KWD 7.76
19.85% below
متوسط 50 يوم / 200 يوم
KWD 6.79
8.45% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -29.10 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-83.17%
أقل من متوسط القطاع (-51.02%)
ROIC-68.68%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio10.67
Interest CoverageN/A

التقييم

PE (TTM)
-10.23
أقل من متوسط القطاع (-1.98)
P/B Ratio6.49
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (44 نظير)
المقياس السهم وسيط القطاع
P/E -10.2 -2.0
P/B 6.5 5.1
ROE % -83.2 -51.0
Net Margin % — -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -32.77 M
ROE -83.17% ROA -74.03%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -29.10 M
ROIC -68.68% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10.67
Interest Coverage N/A Asset Turnover N/A
Working Capital 50.96 M Tangible Book Value 51.62 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10.23 Forward P/E N/A
P/B Ratio 6.49 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -8.68%
Market Cap 335.15 M Enterprise Value 331.82 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -0.54 OCF / Share -0.54
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 88.82%
SBC-Adj. FCF -32.32 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -32.77 M -24.44 M -19.38 M -13.68 M -13.59 M
EPS (Diluted) — — — — —
Gross Profit — — — — —
Operating Income -34.40 M -26.68 M -21.27 M -14.00 M -13.65 M
EBITDA — — — — —
R&D Expenses 24.61 M 19.06 M 13.11 M 7.84 M 8.77 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 28,000.0 30,000.0 43,000.0 28,000.0 28,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 61.37 M 46.35 M 54.16 M 34.40 M 45.55 M
Total Liabilities — — — — —
Shareholders' Equity 56.11 M 40.72 M 51.06 M 31.83 M 44.02 M
Total Debt — — — — —
Cash & Equivalents 15.65 M 3.03 M 4.54 M 4.73 M 4.71 M
Current Assets 60.63 M 44.61 M 53.68 M 33.84 M 45.44 M
Current Liabilities 5.13 M 5.39 M 2.79 M 2.17 M 1.52 M